Genome-Wide CRISPR/Cas9 Library Screening Identified that DUSP4 Deficiency Induces Lenvatinib Resistance in Hepatocellular Carcinoma

Background: Lenvatinib is in a first-line therapy for advanced hepatocellular carcinoma (HCC). However, drug resistance is one of the principal obstacles for treatment failure. The molecular mechanism of Lenvatinib resistance has not been well investigated. Materials and methods: A genome-wide CRISP...

Descripción completa

Detalles Bibliográficos
Autores principales: Huang, Shanzhou, Ma, Zuyi, Zhou, Qi, Wang, Aimei, Gong, Yuanfeng, Li, Zhenchong, Wang, Shujie, Yan, Qian, Wang, Dongping, Hou, Baohua, Zhang, Chuanzhao
Formato: Online Artículo Texto
Lenguaje:English
Publicado: Ivyspring International Publisher 2022
Materias:
Research Paper
Acceso en línea:https://www.ncbi.nlm.nih.gov/pmc/articles/PMC9295068/
https://www.ncbi.nlm.nih.gov/pubmed/35864956
http://dx.doi.org/10.7150/ijbs.69969

Internet

https://www.ncbi.nlm.nih.gov/pmc/articles/PMC9295068/
https://www.ncbi.nlm.nih.gov/pubmed/35864956
http://dx.doi.org/10.7150/ijbs.69969

Ejemplares similares